DJIA 17,279.74 13.75 0.08%
NASDAQ 4,579.79 -13.64 -0.30%
S&P 500 2,010.40 -0.96 -0.05%
market minute promo

Medivation, Inc. (NASDAQ: MDVN)

company name or ticker

Earnings Preview: Abbott Laboratories and Johnson & Johnson

Abbott Laboratories and Johnson & Johnson are slated to report second quarter earnings this week. Here's what you need to know.

Medivation Announces Change in Executive Management Team; Dawn Svoronos To Chief Commercial Officer

Medivation Set To Go Higher As Prostate Cancer Drug Xtandi Quickly Approaches Blockbuster Status

Is This Johnson & Johnson's Worst Nightmare?

Some of Johnson & Johnson's top-performing drugs could soon see a major dip in sales. Here's why.

3 Reasons to Buy Medivation Inc.

Medivation is mid-cap biopharma that looks to have a promising future based on the commercial performance of its prostate cancer drug. Here's what you need to know.

What Does Dendreon Need To Succeed?

3 Stocks Underperforming Today In The Health Care Sector

Roche Holding Ltd Is Betting Billions on This New Blockbuster

Roche's move to pay as much as $2 billion for Seragon is a major vote of confidence for an unproven therapy approach

Aegis Capital Believes Seragon Deal Underscores Value In Medivation

Biotech 101: Off-Label Prescriptions

Investors can learn something from Medivation, GlaxoSmithKline, Amarin and AstraZeneca.
See More Articles...